Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Restricted access

The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations for the management of adult patients with HL. The NCCN panel meets at least annually to review comments from reviewers within their institutions, examine relevant data, and reevaluate and update their recommendations. Current management of classic HL involves initial treatment with chemotherapy alone or combined modality therapy followed by restaging with PET/CT to assess treatment response. Overall, the introduction of less toxic and more effective regimens has significantly advanced HL cure rates. This portion of the NCCN Guidelines focuses on the management of classic HL.

Individual Disclosures for the NCCN Hodgkin Lymphoma Panel

TU1

  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:730.

  • 2.

    Swerdlow SH, Campo E, Harris NL, . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed. Lyon: IARC Press; 2017.

    • Search Google Scholar
    • Export Citation
  • 3.

    Podoloff DA, Advani RH, Allred C, . NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 2007;5(Suppl 1):S1S22., quiz S23–S2.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    American College of Radiology. ACR-SPR Practice Parameters for Performing FDG-PET/CT in Oncology. 2016. Accessed January 24, 2020. Available at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/FDG-PET-CT.pdf?la=en

  • 5.

    Boellaard R, Delgado-Bolton R, Oyen WJ, . FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015;42:328354.

  • 6.

    El-Galaly T, Mylam KJ, Brown P, . Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission is associated with low positive predictive value and high costs. Haematologica 2012;97:931936.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    El-Galaly TC, Mylam KJ, Bøgsted M, . Role of routine imaging in detecting recurrent lymphoma: a review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. Am J Hematol 2014;89:575580.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Gandikota N, Hartridge-Lambert S, Migliacci JC, . Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy. Cancer 2015;121:19851992.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Mocikova H, Obrtlikova P, Vackova B, . Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. Ann Oncol 2010;21:12221227.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    El-Galaly TC, d’Amore F, Mylam KJ, . Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 2012;30:45084514.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Salaun PY, Gastinne T, Bodet-Milin C, . Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin’s lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging 2009;36:18131821.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Moulin-Romsee G, Hindié E, Cuenca X, . (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 2010;37:10951105.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Kumar A, Casulo C, Yahalom J, . Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood 2016;128:14581464.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Straus DJ, Portlock CS, Qin J, . Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:34833489.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    van der Kaaij MA, Heutte N, Meijnders P, . Premature ovarian failure and fertility in long-term survivors of Hodgkin’s lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d’Etude des Lymphomes de l’Adulte Cohort Study. J Clin Oncol 2012;30:291299.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Sieniawski M, Reineke T, Nogova L, . Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008;111:7176.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    van der Kaaij MA, van Echten-Arends J, Simons AH, . Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol 2010;28:168179.

  • 18.

    Carbone PP, Kaplan HS, Musshoff K, . Report of the committee on Hodgkin’s disease staging classification. Cancer Res 1971;31:18601861.

    • Search Google Scholar
    • Export Citation
  • 19.

    Cheson BD, Fisher RI, Barrington SF, . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:30593067.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Mauch P, Goodman R, Hellman S. The significance of mediastinal involvement in early stage Hodgkin’s disease. Cancer 1978;42:10391045.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Lister TA, Crowther D, Sutcliffe SB, . Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989;7:16301636.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Henry-Amar M, Friedman S, Hayat M, . Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. Ann Intern Med 1991;114:361365.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Tubiana M, Henry-Amar M, Hayat M, . Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease. Cancer 1984;54:885894.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Hasenclever D, Diehl V, Armitage JO, . A prognostic score for advanced Hodgkin’s disease. N Engl J Med 1998;339:15061514.

  • 25.

    Moccia AA, Donaldson J, Chhanabhai M, . International Prognostic Score in advanced-stage Hodgkin’s lymphoma: altered utility in the modern era. J Clin Oncol 2012;30:33833388.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:18441854.

  • 27.

    Barrington SF, Mikhaeel NG, Kostakoglu L, . Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014;32:30483058.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005;104:10661074.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    de Wit M, Bohuslavizki KH, Buchert R, . 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann Oncol 2001;12:2937.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Guay C, Lépine M, Verreault J, . Prognostic value of PET using 18F-FDG in Hodgkin’s disease for posttreatment evaluation. J Nucl Med 2003;44:12251231.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Sher DJ, Mauch PM, Van Den Abbeele A, . Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin’s lymphoma: the importance of involved-field radiotherapy. Ann Oncol 2009;20:18481853.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Meignan M, Gallamini A, Haioun C, . Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 2010;51:21712180.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Meignan M, Gallamini A, Itti E, . Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 2012;53:18761881.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Barrington SF, Qian W, Somer EJ, . Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:18241833.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging 2017; 44(S1, Suppl 1)97110.

  • 36.

    Schaefer NG, Taverna C, Strobel K, . Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed? Radiology 2007;244:257262.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Barrington SF, Kirkwood AA, Franceschetto A, . PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood 2016;127:15311538.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Biggi A, Gallamini A, Chauvie S, . International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med 2013;54:683690.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Gallamini A, Barrington SF, Biggi A, . The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 2014;99:11071113.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Gallamini A, Kostakoglu L. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? Blood 2012;120:49134920.

  • 41.

    Radford J, Illidge T, Counsell N, . Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 2015;372:15981607.

  • 42.

    Aldin A, Umlauff L, Estcourt LJ, . Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev 2019;9:CD012643.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Kobe C, Goergen H, Baues C, . Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma. Blood 2018;132:22732279.

  • 44.

    André MPE, Girinsky T, Federico M, . Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2017;35:17861794.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45.

    Johnson P, Federico M, Kirkwood A, . Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 2016;374:24192429.

  • 46.

    Gallamini A, Hutchings M, Avigdor A, . Early interim PET scan in Hodgkin lymphoma: where do we stand? Leuk Lymphoma 2008;49:659662.

  • 47.

    Terasawa T, Lau J, Bardet S, . Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:19061914.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Lynch RC, Advani RH. Risk-adapted treatment of advanced Hodgkin lymphoma with PET-CT. Am Soc Clin Oncol Educ Book 2016;35:e376e385.

  • 49.

    Dabaja BS, Hoppe BS, Plastaras JP, . Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood 2018;132:16351646; erratum in: Blood 2019;133:1385–1385.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Li J, Dabaja B, Reed V, . Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys 2011;81:167174.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Hoppe BS, Flampouri S, Su Z, . Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012;84:449455.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Girinsky T, Pichenot C, Beaudre A, . Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 2006;64:218226.

    • Search Google Scholar
    • Export Citation
  • 53.

    Nieder C, Schill S, Kneschaurek P, . Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiat Oncol 2007;2:20.

  • 54.

    Paumier A, Ghalibafian M, Gilmore J, . Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 2012;82:15221527.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Filippi AR, Ragona R, Fusella M, . Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy. Pract Radiat Oncol 2013;3:216222.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Charpentier A-M, Conrad T, Sykes J, . Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose. Pract Radiat Oncol 2014;4:174180.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Filippi AR, Ciammella P, Piva C, . Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2014;89:370375.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Voong KR, McSpadden K, Pinnix CC, . Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma. Radiat Oncol 2014;9:94.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Girinsky T, van der Maazen R, Specht L, . Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006;79:270277.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Paumier A, Ghalibafian M, Beaudre A, . Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011;80:199205.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Specht L, Yahalom J, Illidge T, .ILROG. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 2014;89:854862.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Hoskin PJ, Díez P, Williams M, . Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol (R Coll Radiol) 2013;25:4958.

  • 63.

    Grégoire V, Mackie TR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). Cancer Radiother 2011;15:555559.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Bonadonna G, Bonfante V, Viviani S, . ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 2004;22:28352841.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Advani RH, Hoppe RT, Baer D, . Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol 2013;24:10441048.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 66.

    Engert A, Plütschow A, Eich HT, . Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 2010;363:640652.

  • 67.

    Dühmke E, Franklin J, Pfreundschuh M, . Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001;19:29052914.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Gustavsson A, Osterman B, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in Hodgkin’s lymphoma. Acta Oncol 2003;42:589604.

  • 69.

    Fuchs M, Goergen H, Kobe C, . Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. J Clin Oncol 2019;37:28352845.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 70.

    Straus DJ, Jung SH, Pitcher B, . CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 2018;132:10131021.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Advani RH, Hong F, Fisher RI, . Randomized phase III trial comparing ABVD plus radiotherapy with the stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 trial. J Clin Oncol 2015;33:19361942.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 72.

    Gordon LI, Hong F, Fisher RI, . Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013;31:684691.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 73.

    von Tresckow B, Plütschow A, Fuchs M, . Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012;30:907913.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 74.

    Engert A, Haverkamp H, Kobe C, . Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:17911799.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 75.

    Canellos GP, Anderson JR, Propert KJ, . Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:14781484.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Merli F, Luminari S, Gobbi PG, . Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol 2016;34:11751181.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Viviani S, Zinzani PL, Rambaldi A, . ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203212.

  • 78.

    Press OW, Li H, Schöder H, . US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol 2016;34:20202027.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 79.

    Stephens DM, Li H, Schöder H, . Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood 2019;134:12381246.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Gallamini A, Tarella C, Viviani S, . Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: Long-term results of the GITIL/FIL HD 0607 Trial. J Clin Oncol 2018;36:454462.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Borchmann P, Haverkamp H, Diehl V, . Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011;29:42344242.

    • Search Google Scholar
    • Export Citation
  • 82.

    Engert A, Diehl V, Franklin J, . Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:45484554.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Kriz J, Reinartz G, Dietlein M, . Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 2015;92:4653.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 84.

    Borchmann P, Goergen H, Kobe C, . PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017;390:27902802.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 85.

    Casasnovas RO, Bouabdallah R, Brice P, . PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 2019;20:202215.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Carde P, Karrasch M, Fortpied C, . Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score ≥3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup trial. J Clin Oncol 2016;34:20282036.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 87.

    Federico M, Luminari S, Iannitto E, . ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009;27:805811.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Mounier N, Brice P, Bologna S, . ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 2014;25:16221628.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 89.

    Connors JM, Jurczak W, Straus DJ, . Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 2018;378:331344.

  • 90.

    Ramchandren R, Advani RH, Ansell SM, . Brentuximab vedotin plus chemotherapy in North American subjects with newly diagnosed stage III or IV Hodgkin lymphoma. Clin Cancer Res 2019;25:17181726.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Johnson PW, Sydes MR, Hancock BW, . Consolidation radiotherapy in patients with advanced Hodgkin’s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol 2010;28:33523359.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Jagadeesh D, Diefenbach C, Evens AM. XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes. Hematol Oncol 2013; 31(S1, Suppl 1)6975.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park) 2008;22:13691379.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Ballova V, Rüffer JU, Haverkamp H, . A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005;16:124131.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 95.

    Böll B, Görgen H, Fuchs M, . ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 2013;31:15221529.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 96.

    Evens AM, Hong F, Gordon LI, . The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol 2013;161:7686.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 97.

    Halbsguth TV, Nogová L, Mueller H, . Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 2010;116:20262032.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 98.

    Böll B, Goergen H, Behringer K, . Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 2016;127:21892192.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 99.

    Stamatoullas A, Brice P, Bouabdallah R, . Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol 2015;170:179184.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Andersen MD, Kamper P, d’Amore A, . The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor . Leuk Lymphoma 2019;60:927933.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Sun H, Atenafu E, Tsang R, . Incidence and predictors of bleomycin pulmonary toxicity in Hodgkin lymphoma (HL) patients treated with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Blood 2011;118:3643.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 102.

    Evens AM, Advani RH, Helenowski IB, . Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol 2018;36:30153022.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Kolstad A, Nome O, Delabie J, . Standard CHOP-21 as first line therapy for elderly patients with Hodgkin’s lymphoma. Leuk Lymphoma 2007;48:570576.

  • 104.

    Friedberg JW, Forero-Torres A, Bordoni RE, . Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood 2017;130:28292837.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 105.

    Friedberg JW, Forero-Torres A, Holkova B, . Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma. J Clin Oncol 2018;36(15_suppl):7542.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 106.

    Levis A, Anselmo AP, Ambrosetti A, .Intergruppo Italiano Linfomi (IIL). VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 2004;15:123128.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Proctor SJ, Wilkinson J, Jones G, . Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood 2012;119:60056015.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Böll B, Bredenfeld H, Görgen H, . Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 2011;118:62926298.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Linch DC, Winfield D, Goldstone AH, . Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993;341:10511054.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Schmitz N, Pfistner B, Sextro M, . Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002;359:20652071.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Moskowitz CH, Kewalramani T, Nimer SD, . Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol 2004;124:645652.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 112.

    Sirohi B, Cunningham D, Powles R, . Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol 2008;19:13121319.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    Brice P, Bouabdallah R, Moreau P, . Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Bone Marrow Transplant 1997;20:2126.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Moskowitz CH, Nimer SD, Zelenetz AD, . A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616623.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Moskowitz CH, Yahalom J, Zelenetz AD, . High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 2010;148:890897.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Josting A, Franklin J, May M, . New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol 2002;20:221230.

    • Search Google Scholar
    • Export Citation
  • 117.

    Sureda A, Constans M, Iriondo A, . Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol 2005;16:625633.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    Stiff PJ, Unger JM, Forman SJ, . The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003;9:529539.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 119.

    Wheeler C, Eickhoff C, Elias A, . High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin’s disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997;3:98106.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Horning SJ, Chao NJ, Negrin RS, . High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801813.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Jabbour E, Hosing C, Ayers G, . Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007;109:24812489.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Mocikova H, Pytlik R, Markova J, . Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. Leuk Lymphoma 2011;52:16681674.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Smeltzer JP, Cashen AF, Zhang Q, . Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant 2011;17:16461652.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Moskowitz CH, Matasar MJ, Zelenetz AD, . Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012;119:16651670.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    The International ChlVPP Treatment Group. ChlVPP therapy for Hodgkin’s disease: experience of 960 patients. Ann Oncol 1995;6:167172.

  • 126.

    Abali H, Urün Y, Oksüzoğlu B, . Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 2008;26:401406.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 127.

    Aparicio J, Segura A, Garcerá S, . ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol 1999;10:593595.

  • 128.

    Colwill R, Crump M, Couture F, . Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995;13:396402.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 129.

    Josting A, Rudolph C, Reiser M, . Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol 2002;13:16281635.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Labrador J, Cabrero-Calvo M, Pérez-López E, . ESHAP as salvage therapy for relapsed or refractory Hodgkin’s lymphoma. Ann Hematol 2014;93:17451753.

  • 131.

    Martín A, Fernández-Jiménez MC, Caballero MD, . Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease. Br J Haematol 2001;113:161171.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 132.

    Phillips JK, Spearing RL, Davies JM, . VIM-D salvage chemotherapy in Hodgkin’s disease. Cancer Chemother Pharmacol 1990;27:161163.

  • 133.

    Rodriguez MA, Cabanillas FC, Hagemeister FB, . A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 1995;6:609611.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 134.

    Bartlett NL, Niedzwiecki D, Johnson JL, . Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 2007;18:10711079.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 135.

    Santoro A, Magagnoli M, Spina M, . Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica 2007;92:3541.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 136.

    Crump M, Kuruvilla J, Couban S, . Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014;32:34903496.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Gopal AK, Press OW, Shustov AR, . Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 2010;51:15231529.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 138.

    Gutierrez A, Rodriguez J, Martinez-Serra J, . Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. OncoTargets Ther 2014;7:20932100.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 139.

    Moskowitz AJ, Hamlin PA, Jr., Perales M-A, . Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31:456460.

  • 140.

    Fehniger TA, Larson S, Trinkaus K, . A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:51195125.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 141.

    Johnston PB, Inwards DJ, Colgan JP, . A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85:320324.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Santoro A, Mazza R, Pulsoni A, . Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study. J Clin Oncol 2016;34:32933299.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 143.

    Budde LE, Wu D, Martin DB, . Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol 2018;183:601607.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 144.

    Younes A, Bartlett NL, Leonard JP, . Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:18121821.

  • 145.

    Younes A, Gopal AK, Smith SE, . Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012;30:21832189.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 146.

    Gopal AK, Chen R, Smith SE, . Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015;125:12361243.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 147.

    Moskowitz AJ, Schöder H, Yahalom J, . PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol 2015;16:284292.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 148.

    Chen R, Palmer JM, Martin P, . Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2015;21:21362140.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 149.

    Garcia-Sanz R, Sureda A, Alonso-Alvarez S, . Evaluation of the regimen brentuximab vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a phase I-II trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Blood 2015;126:582.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 150.

    LaCasce AS, Bociek G, Sawas A, . Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood 2015;126:3982.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 151.

    O’Connor OA, Lue JK, Sawas A, . Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol 2018;19:257266.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 152.

    Herrera AF, Moskowitz AJ, Bartlett NL, . Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2018;131:11831194.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 153.

    Herrera AF, Manley T, Sacchi M, . Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: Long-term follow-up results from the single-arm phase 1/2 study. Blood 2019;134(Supplement_1):238.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 154.

    Moskowitz CH, Nademanee A, Masszi T, . Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385:18531862.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 155.

    Ansell SM, Lesokhin AM, Borrello I, . PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015;372:311319.

  • 156.

    Armand P, Engert A, Younes A, . Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 2018;36:14281439.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 157.

    Armand P, Shipp MA, Ribrag V, . Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 2016;34:37333739.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 158.

    Chen R, Zinzani PL, Fanale MA, . Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35:21252132.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 159.

    Younes A, Santoro A, Shipp M, . Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17:12831294.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 160.

    Josting A, Nogová L, Franklin J, . Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005;23:15221529.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 161.

    Constine LS, Yahalom J, Ng AK, . The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2018;100:11001118.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 162.

    Evens AM, Altman JK, Mittal BB, . Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin’s lymphoma. Ann Oncol 2007;18:679688.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 163.

    Fernández de Larrea C, Martínez C, Gaya A, . Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin’s lymphoma followed by autologous stem-cell transplantation. Ann Oncol 2010;21:12111216.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 164.

    Alvarez I, Sureda A, Caballero MD, . Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006;12:172183.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 165.

    Sureda A, Canals C, Arranz R, . Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310317.

    • Search Google Scholar
    • Export Citation
  • 166.

    Castagna L, Bramanti S, Devillier R, . Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone Marrow Transplant 2017;52:683688; erratum in: Bone Marrow Transplant 2017;52:797.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 167.

    Böll B, Goergen H, Arndt N, . Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. J Clin Oncol 2013;31:44314437.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 168.

    Chen RW, Palmer J, Martin P, . Results of a phase II trial of brentuximab vedotin as first line salvage therapy in relapsed/refractory HL prior to AHCT. Blood 2014;124:501.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2440 2440 2372
PDF Downloads 828 828 800
EPUB Downloads 0 0 0